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Abstract. A wet-chemistry biochemical analyzer was assessed for in-practice veterinary use. Its 13 
small size may mean a cost-effective method for low-throughput in-house biochemical analyses 14 
for first-opinion practice. The objectives of our study were to determine imprecision, total 15 
observed error, and acceptability of the analyzer for measurement of common canine and feline 16 
serum analytes, and to compare clinical sample results to those from a commercial reference 17 
analyzer. Imprecision was determined by within- and between-run repeatability for canine and 18 
feline pooled samples, and manufacturer-supplied quality control material (QCM). Total 19 
observed error (TEobs) was determined for pooled samples and QCM. Performance was assessed 20 
for canine and feline pooled samples by sigma metric determination. Agreement and errors 21 
between the in-practice and reference analyzers were determined for canine and feline clinical 22 
samples by Bland–Altman and Deming regression analyses. Within- and between-run precision 23 
was high for most analytes, and TEobs(%) was mostly lower than total allowable error. 24 
Performance based on sigma metrics was good (σ > 4) for many analytes and marginal (σ > 3) 25 
for most of the remainder. Correlation between the analyzers was very high for most canine 26 
analytes and high for most feline analytes. Between-analyzer bias was generally attributed to 27 
high constant error. The in-practice analyzer showed good overall performance, with only 28 
calcium and phosphate analyses identified as significantly problematic. Agreement for most 29 
analytes was insufficient for transposition of reference intervals, and we recommend that in-30 
practice–specific reference intervals be established in the laboratory. 31 
 32 
Key words: Cats; dogs; instrumentation; point-of-care systems; validation studies. 33 
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Introduction 35 
Continuous advancement in diagnostic technology has increased both instrument reliability and 36 
the frequency of its in-house use in veterinary clinical practice. Hematology and biochemistry 37 
analyzers are the most frequently employed in first-opinion practice and have the advantages of 38 
being rapid and mostly cost-effective. Dry-chemistry analyzers are generally considered more 39 
cost-effective than wet-chemistry analyzers for low-throughput applications. For reference 40 
laboratories with high numbers of samples, large wet-chemistry analyzers offer significant 41 
savings given low reagent cost. The relatively rapid expiration of these reagents once opened 42 
precludes their use in low-throughput laboratories, however, because significant wastage would 43 
offset any savings. A smaller wet-reagent analyzera is available for veterinary in-house use, 44 
although, at present, independent performance evaluation studies have not been published, to our 45 
knowledge. The aims of this study were 1) to determine the precision, total observed error 46 
(TEobs), and acceptability of the in-practice analyzer for measuring 12 common canine and feline 47 
serum biochemical analytes, and 2) to compare the results obtained from clinical samples using 48 
the in-practice analyzer to those generated from a reference commercial, high-throughput wet-49 
chemistry analyzer.b 50 
Materials and methods 51 
Samples 52 
Blood samples from 66 dogs and 59 cats submitted to the Diagnostic Laboratories (University of 53 
Bristol, Langford, Bristol, UK) between March 2013 and March 2014 were included in the study. 54 
The samples included those for routine pre-anesthetic screening as well as investigation of a 55 
wide range of clinical signs and diseases. Whole blood submitted for biochemical analysis in 56 
non-anticoagulant (plain) tubesc was allowed to clot and then centrifuged (4°C; 2,000 × g; 5 min) 57 
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before removal of the serum fraction. Excess serum from clinical samples following analysis was 58 
frozen at –20°C for up to 1 year and used in the study with owners’ consent. 59 
Pooled serum samples were also created for both species using excess serum from stored 60 
clinical samples. For simplicity, a single pooled sample from each species was used rather than 61 
multiple samples with different concentrations for all of the different analytes. Canine and feline 62 
pooled samples were created by mixing several samples containing within- or near-reference 63 
concentrations for all analytes in this study, as determined by the reference chemistry analyzer. 64 
Samples that were grossly hemolyzed were excluded from the study. Samples that were 65 
grossly lipemic were analyzed without modification for cholesterol concentration; these samples 66 
were centrifuged at high speed (12,000 × g for 5 min) and the lipid layer removed before further 67 
biochemical analysis. Icteric samples with total bilirubin concentrations >340 µmol/L, as 68 
measured by the reference chemistry analyzer, were excluded from the study to avoid 69 
interference with phosphate measurements, according to the manufacturer’s instructions.9 70 
On the day of testing, frozen serum samples were placed in a water bath (37°C) for 5–10 71 
min to thaw, and then remained at room temperature (23°C, range: 22–25°C) not longer than 1 72 
hour before testing. Analyzer calibration, daily checks, and daily control runs were performed 73 
according to the manufacturers’ instructions before sample analysis. 74 
Quality control material 75 
Quality control material (QCM)d with low, normal, and high values were included in every run 76 
of samples in the reference chemistry analyzer. Two human-derived QCM (Eurocontrol N and 77 
Eurocontrol P)a were run daily on the in-practice analyzer. The analyte concentrations in 78 
Eurocontrol N were all within the manufacturer-defined reference intervals. Analyte 79 
concentrations in Eurocontrol P were abnormal as follows: albumin (ALB), decreased; alkaline 80 
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phosphatase (ALP), increased; alanine aminotransferase (ALT), increased; calcium (Ca), 81 
decreased; cholesterol (Chol), increased; creatinine (Crea), increased; gamma-glutamyl 82 
transferase (GGT), increased; glucose (Glu), increased; phosphate (Phos), increased; total 83 
bilirubin (TBil), increased; total protein (TP), decreased; urea, increased. 84 
All analyzer reagents were from the same batch to ensure consistency, and all analyses 85 
were performed according to the respective manufacturers’ instructions.2,10 The accuracy of the 86 
reference chemistry analyzer methods was assessed by continuous bimonthly participation in an 87 
external quality assurance program (RIQAS, http://www.randox.com/riqas/riqas-eqa-scheme). 88 
Analytes 89 
The following 12 analytes were assessed in this study: ALB, ALP, ALT, Ca, Chol, Crea, GGT, 90 
Glu, Phos, TBil, TP, and urea. The methods employed by the 2 analyzers for measurement of 91 
these analytes are shown in Table 1. 92 
Imprecision 93 
The in-practice analyzer’s imprecision was assessed by within- and between-run repeatability 94 
using the QCM (Eurocontrol N and P) and the canine and feline serum pools. Within-run 95 
repeatability was determined by measuring each analyte in the same sample 10 times 96 
sequentially within the same assay run. Between-run repeatability using the serum pools was 97 
determined by measuring each analyte in the same pool each day for 5 consecutive days.5 98 
Between-run repeatability using the QCM was determined from the daily control values 99 
generated over a 2-month period (10 measurements). 100 
Method comparison and statistical analysis 101 
Individual clinical samples were run simultaneously on the 2 analyzers to minimize between-102 
analyzer error. Dilutions (1 in 2) were performed in 14 canine and 3 feline samples because the 103 
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original ALP (11 canine, 1 feline), ALT (2 feline), and GGT (3 canine) results were outside the 104 
detection limit of the in-practice analyzer methods. All analyses were performed using the 105 
graphing and statistics software Prism.e 106 
Imprecision, TEobs, and sigma metrics 107 
Within- and between-run imprecision was determined by calculation of the coefficient of 108 
variation (CV; %), where CV = 100 × standard deviation (SD)/mean. TEobs(%) for each analyte 109 
was determined by the following formula: TEobs(%) = 2 × CV + bias(%).
5 Bias(%) for each 110 
analyte was calculated using the QCM according to the following formula: bias = (target – 111 
measured)/target, where “target” is the mean analyte value reported by the manufacturer, and 112 
“measured” is the mean analyte value measured by the in-practice analyzer over a 2-month 113 
period.4 Given that 2 different QCMs (Eurocontrol N and P) were used daily, bias was 114 
determined for all analytes from both controls. TEobs(%) for each analyte was assessed in 2 ways: 115 
1) TEobs(%) values for the QCM [TEobs-N(%) and TEobs-P(%)] were calculated for each analyte 116 
using the calculated between-run CV for QCM N and P, and the N- and P-specific bias as 117 
determined above, respectively; 2) species-specific TEobs(%) for each analyte was calculated 118 
using the between-run CV for canine and feline pools, and using QCM bias as determined 119 
above.4 Given that bias was determined for both QCM N and P, species-specific TEobs-N(%) and 120 
TEobs-P(%) was calculated for each analyte for comparison. An in-practice analyzer method was 121 
considered acceptable if TEobs < total allowable error (TEA). Because published TEA values vary 122 
throughout the literature, values were taken from both the guidelines of the American Society for 123 
Veterinary Clinical Pathology and a second published study.5,7 124 
Sigma (σ) metric values were calculated according to the following formula: σ = 125 
(TEA(%) – bias(%))/CV.3,5,7 TEA values were taken from published studies, bias was taken as the 126 
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bias for the QCM N, and CV as the between-run CV for the canine and feline pools.5,7 Where the 127 
TEA values differed between the 2 published studies, σ for both was calculated to generate σTEA-128 
Low and σTEA-High. Interpretation of σ values was performed as follows: >2: poor; >3: marginal; 129 
>4: good; >5: excellent; and >6: world-class.6,11 130 
Method comparison 131 
Data from the clinical samples for all analytes in each species were assessed for normality using 132 
D’Agostino and Pearson omnibus tests. When data sets from both analyzers for each analyte and 133 
species were normally distributed, data were compared using a Student unpaired 2-tailed t-test, 134 
with Welch correction for unequal variances as appropriate. A Wilcoxon rank-sum test was 135 
otherwise used. Similarly, correlations between the 2 analyzers were performed using Pearson 136 
correlation when data for that analyte and species were normally distributed; all other 137 
correlations were performed using Spearman correlation. Correlation coefficients were 138 
interpreted as: 0.9–1 very high correlation; 0.70–0.89 high correlation; 0.50–0.69 moderate 139 
correlation; 0.30–0.49 low correlation; and <0.30 little, if any, correlation (Zady M, Correlation 140 
and simple least squares regression, 2009, https://www.westgard.com/lesson42.htm). 141 
Deming regression analysis was used to determine the mathematical relationship between 142 
the 2 analyzers for each analyte and species, and to determine the constant (intercept) and 143 
proportional (slope) errors. Bland–Altman analysis was used to assess agreement between the 144 
analyzers.1 Agreement was considered good when the 95% limits of agreement (LOA; ± 2 SD) 145 
were narrow, the bias was small, and 95% points fell within the LOA. 146 
Results 147 
Imprecision 148 
 Page 8 of 22 
All within-run CV values were <10% (Table 2). Between-run CV values were <10% except for 149 
Phos (QCM N), ALT (canine serum pool), and Ca (feline serum pool; Table 2). CV values for 150 
GGT (feline serum pool) were not reported. 151 
Quality requirements 152 
All TEobs values were below the lowest published TEA for ALB, ALP, Chol, Crea, GGT, Glu, 153 
and TP (Table 3). Analytes for which some TEobs values were over the lower TEA but lower than 154 
the higher TEA were ALT and TBil. For Ca and Phos, more than 1 TEobs was above the higher 155 
TEA. All σTEA-High were >3 except for Ca, Phos, and TP (feline serum pool only; Table 4). Many 156 
σTEA-Low values were also >3; TBil was the only additional analyte with a σTEA-Low <3 in both 157 
species. 158 
Method comparison using clinical samples 159 
Chol, Glu, and urea measurements were not significantly different between analyzers for clinical 160 
samples in either species, whereas ALB, ALP, Phos, TBil, and TP measurements were 161 
significantly different between analyzers in both canine and feline samples (Table 5). 162 
Correlations between the analyzers were <0.7 for canine Phos, feline Ca, and feline GGT (Table 163 
6). 164 
The most substantial bias values were seen for canine ALP (242% reference median) and 165 
TBil (218%), and for feline ALP (–307%), ALT (89%), GGT (110%), and TBil (250%; Tables 7, 166 
8). The widest 95% LOA were observed for ALP, ALT, GGT, and TBil. 167 
Discussion 168 
Large-scale wet-chemistry analyzers are employed by most veterinary diagnostic laboratories 169 
because of their speed, overall reliability, and consistency of results. The costs of running these 170 
analyzers can be prohibitive for general practitioners in first-opinion practice, however, 171 
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especially when throughput is relatively low. Validation of smaller, less-expensive analyzers is 172 
therefore of most benefit to practices who desire wet-chemistry analysis without the incumbent 173 
costs. 174 
The results of the repeatability study show that the within-run CV values for both QCM 175 
and both serum pools were mostly ≤5% (42/47 values), and all were <9%. The majority of 176 
between-run CV values (38/47) were also ≤5%, with all values <14%. The in-practice analyzer 177 
therefore has high precision for measurement of most analytes in dogs and cats, and moderate 178 
precision for the remaining analytes. 179 
The between-cat variation in GGT in our study, even with the inclusion of cats with 180 
apparent cholestasis (based on ALP and TBil values), was relatively very low compared to that 181 
for the dog. Our maximum observed feline GGT activity measured by the in-practice analyzer 182 
was 12 IU/L, although TBil and ALP were normal in this cat. The maximum reference analyzer 183 
GGT activity was 5 IU/L (in-practice analyzer: 4 IU/L); ALP and TBil were both markedly 184 
increased in this sample. In contrast, the maximum canine GGT measured was 778 IU/L. In our 185 
experience, even cats with marked cholestasis are observed to have substantially lower GGT 186 
levels than other species, and milder increases following extrahepatic bile duct obstruction are 187 
seen in the cat than in the dog.8 With such narrow between-cat variation, GGT values need to be 188 
reported to at least 1 decimal place for meaningful repeatability analysis because each 1 IU/L 189 
represents ≥8% of the maximum value. GGT is measured to zero decimal places using the in-190 
practice analyzer, however, which generated very large and meaningless CV values. The results 191 
were therefore excluded from the study, and dependent calculations (feline GGT TEobs and σ 192 
values) were not performed. This issue has been encountered in other similar studies, and results 193 
were likewise excluded.4 194 
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QCM TEobs-N(%) and TEobs-P(%) were broadly similar for all analytes, and, with the 195 
exception of canine ALT, were also broadly similar to the pooled samples. Seven of the analytes 196 
(ALB, ALP, Chol, Crea, GGT, Glu, and TP) had all TEobs(%) values below the lower published 197 
TEA, which demonstrates acceptability based on observed error for these methods. TEobs(%) for 198 
TBil and ALT were lower than the higher TEA, which also suggests acceptability for these 199 
methods. TEobs-P(%) for canine urea was the only TEobs value for this analyte above TEA, but the 200 
increase was small (2%) and likely to be of little significance. Several TEobs(%) for Ca and all 201 
TEobs(%) for Phos were well above the TEA, which suggests the in-practice analyzer methods are 202 
not acceptable for measuring these analytes based on observed error. 203 
The computed σ metric value for an assay and its graphical representation, the MEDx 204 
chart, are performance indicators used to show assay reliability.6 This information complements 205 
allowable error analysis and ensures that the minimum desired quality standards for an assay are 206 
met. In addition, these analyses are used to determine the stringency of quality control rules for 207 
that particular assay, with lower values requiring a greater number of, and more stringent, rules 208 
to ensure error detection. The highest σ values in our study were generally observed for analytes 209 
with TEobs < TEA, which is in part caused by low CV and/or bias, and relatively high TEA. 210 
Canine analytes with σTEA-Low values >4 (good performance) were ALB, ALP, Chol, Crea, and 211 
Glu, with TBil σTEA-High >4. ALT, GGT, TP, and urea were all >3 for σTEA-Low and/or σTEA-High, 212 
which suggests that the performance for measuring these analytes is likely to be sufficient but 213 
with room for improvement. For feline samples, analytes with σTEA-Low >4 were ALB, Chol, 214 
Crea, Glu, and urea, with σTEA-High >4 for ALP, ALT, and TBil. Ca and Phos performance in both 215 
species, and TP performance in the cat, was poor or worse. No single factor was identified to 216 
explain the low feline TP σ value, as bias and CV were both low. A relatively low TEA of 10% 217 
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(much lower than ALB, for example) appears contributory, however, and a TEA of 12% would 218 
move the σ value to >3. 219 
Ca performance is likely to be affected, at least in part, by the relatively low TEA 220 
compared to most other analytes. A low TEA is expected for analytes that require tight biological 221 
control, and so the performance requirement is high to ensure that small deviations are detected 222 
accurately and reliably. Ca bias was 2% for QCM N, with between-run CV of 5% and 10% in the 223 
dog and cat, respectively. This suggests that improvement in precision is required to increase the 224 
σ value. 225 
High TEobs(%) and very poor σ values for Phos measurement appear to be the result of 226 
high bias(%): QCM N generated a bias of –27%, and QCM P a bias of 14%, despite controls 227 
falling within the recommended ranges given in the technical inserts. This suggests there may 228 
have been a failure in calibration. Recalibration of the instrument with 2 different batches of 229 
QCM N and P did not affect the Phos measurements of the QCM (not shown). Bias values for 230 
the other analytes were a mixture of positive and negative, and of relatively small magnitude for 231 
most analytes, which excludes errors in reconstitution of 1 or both of the QCM. Failure of 232 
calibration is therefore potentially the result of either incorrect concentration of Phos in both 233 
QCMs (1 is unlikely given that bias was large for both QCM but in different directions) or a 234 
technical fault in the assay. 235 
Correlation between the analyzers was mostly very high for canine samples, with Ca 236 
showing moderate correlation and Phos showing poor correlation. The datasets for many canine 237 
analytes were significantly different between the analyzers, however, and the Deming regression 238 
analyses revealed that this was mostly because of constant error in the measurement of the 239 
analytes by the in-practice analyzer relative to the reference analyzer. Correlations were also 240 
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high or very high for feline samples, with moderate correlation seen for ALB and Chol, and poor 241 
for Ca and GGT. Major differences between the analyzer datasets also appeared to be the result 242 
of constant rather than proportional error with the exception of GGT. 243 
Agreement between the analyzers was assessed from the results of the Bland–Altman 244 
analysis. For many of the analytes, ≥95% of results fell within the 95% LOA; however, the bias 245 
was too large and/or 95% LOA was too wide to be meaningful.1 Canine Glu and TP, and feline 246 
TP, had a small mean bias and relatively narrow LOA, as well as ≥95% results within the 95% 247 
LOA, consistent with good agreement. Agreement for the remaining analytes was considered 248 
unacceptable. 249 
Our study had some limitations. Ideally, precision, TEobs, and σ metrics are calculated for 250 
2 or 3 different analyte levels (low, within-reference, and high) to show performance over the 251 
range of clinical samples. In our study, we determined 1 precision, TEobs, and σ metric value for 252 
each analyte given the use of a single pooled sample for each species. It must also be noted that 253 
veterinary TEA values are generally based on results from canine studies, and all TEA values in 254 
this study were defined for dogs. It is therefore possible that these values are not always 255 
appropriate for cats when reference intervals differ significantly between species. Complete 256 
validation of a method should include reportable range, recovery, and interference 257 
measurements. For simplicity, these were not performed during this study, and it is 258 
recommended that these be determined prior to clinical use. Last, duplicate measurement of 259 
analytes in the clinical samples may have improved agreement between the analyzers. Were the 260 
interchangeability of reference intervals between the analyzers of critical importance, this would 261 
have been preferred; for the purposes of this study and other studies, it was not necessary.4 262 
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Table 1. Methods employed by the in-practice and reference analyzers for biochemical 301 
analysis.* 302 
Analyte In-practice analyzer Reference analyzer 
ALB Bromocresol green Bromocresol green 
ALP DGKC at 37°C, DEA IFCC at 37°C, AMP buffer 
ALT IFCC (without P5P) at 37°C IFCC (with P5P) at 37°C 
Ca Arsenazo Arsenazo 
Chol GOD-PAP Cholesterol oxidase/peroxidase colorimetric 
Crea Jaffé modified Enzymatic colorimetric 
GGT IFCC (GLUCANA) at 37°C IFCC (GLUCANA) at 37°C 
Glu GOD-PAP Hexokinase 
Phos Ammonium molybdate Ammonium molybdate 
TBil Acid diazo coupling Acid diazo coupling 
TP Biuret modified Biuret 
Urea Urease Urease 
* ALB = albumin; ALP = alkaline phosphatase; ALT = alanine aminotransferase; Ca = calcium; 303 
Chol = cholesterol; Crea = creatinine; GGT = gamma-glutamyl transferase; Glu = glucose; Phos 304 
= phosphate; TBil = total bilirubin; TP = total protein; DGKC = German Society for Clinical 305 
Chemistry (now German Society for Clinical Chemistry and Laboratory Medicine, Bonn, 306 
Germany); DEA = diethanolamine; International Federation of Clinical Chemistry and 307 
Laboratory Medicine (Milano, Italy); AMP = 2-amino-2-methyl-1-propanol; P5P = pyridoxine-308 
5-phosphate; GLUCANA = γ-glutamyl-3-carboxy-4-nitroanilide; GOD-PAP = Trinder oxidase-309 
peroxidase-aminophenazone. 310 
311 
 Page 16 of 22 
Table 2. Within- and between-run precision data for quality control material (Eurocontrol N and 312 
Eurocontrol P; QCM N and P, respectively) and serum pools using the in-practice analyzer.* 313 
Analyte 
Within-run CV (%) Between-run CV (%) 









ALB 0.98 1.80 1.34 2.21 2.18 1.17 2.16 2.46 
ALP 2.80 1.59 3.11 2.87 2.19 1.55 1.81 5.22 
ALT 8.22 2.40 3.76 4.79 2.68 1.90 11.71 4.98 
Ca 1.75 1.12 1.88 0.93 1.96 1.07 4.76 10.61 
Chol 1.84 1.64 1.78 2.03 1.41 2.17 0.24 1.74 
Crea 1.62 0.75 3.51 1.49 5.68 4.20 2.33 1.58 
GGT 2.95 2.26 7.44 NA 1.29 2.79 5.08 NA 
Glu 2.43 3.08 1.48 2.22 2.23 2.31 1.66 2.12 
Phos 5.07 1.77 2.96 3.19 13.72 7.21 5.39 4.09 
TBil 2.91 1.13 3.51 6.77 4.51 1.30 3.17 7.28 
TP 1.90 1.93 2.58 2.61 0.54 2.70 1.88 2.97 
Urea 2.70 2.52 5.48 3.10 5.15 1.58 3.88 1.96 
* CV = coefficient of variation; ALB = albumin; ALP = alkaline phosphatase; ALT = alanine 314 
aminotransferase; Ca = calcium; Chol = cholesterol; Crea = creatinine; GGT = gamma-glutamyl 315 
transferase; Glu = glucose; Phos = phosphate; TBil = total bilirubin; TP = total protein; NA = not 316 
applicable (see Discussion section). 317 
318 
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Table 3. Quality control material (QCM) bias(%) and total observed error [TEobs(%)] for the in-319 
practice analyzer, together with published total allowable error (TEA).* 320 
Analyte 
QCM Serum pools 
TEA† Bias-N Bias-P TEobs-N TEobs-P 
Dog Cat 
TEobs-N TEobs-P TEobs-N TEobs-P 
ALB –2.0 –9.5 6 12 6 14 7 14 15, 25 
ALP 4.0 1.4 8 4 8 5 14 12 25§, 25 
ALT –7.3 2.5 13 6 31 26 17 12 25, 50 
Ca 2.5 9.2 6 11 12 19‡ 24‡ 30‡ 10, 14 
Chol –0.8 0.6 4 5 1 1 4 4 20 
Crea –6.0 –3.9 17 12 11 9 9 7 17, 20 
GGT –2.7 –7.9 5 13 13 18 NA NA 20 
Glu –4.3 –5.1 9 10 8 8 8 9 20, 20 
Phos –27.3 14.4 55‡ 29‡ 38‡ 25‡ 35‡ 23‡ 15, 20 
TBil –17.5 –11.2 27 14 24 18 32 26 30¦, 50 
TP 2.9 4.2 4 10 7 8 9 10 10, 10 
Urea –1.8 –10.3 12 13 10 18‡ 6 14 12, 16 
* N, P = Eurocontrol N and Pa, respectively; ALB = albumin; ALP = alkaline phosphatase; ALT 321 
= alanine aminotransferase; Ca = calcium; Chol = cholesterol; Crea = creatinine; GGT = gamma-322 
glutamyl transferase; Glu = glucose; Phos = phosphate; TBil = total bilirubin; TP = total protein; 323 
NA = not applicable. 324 
† Published TEA values.5,7 325 
‡ TEobs > TEA. 326 
§ 20% desirable.5 327 
¦ 25% desirable.5 328 
329 
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Table 4. Sigma (σ) values for canine and feline pooled serum measured using the in-practice 330 
analyzer.* 331 
Analyte 
Canine pooled serum Feline pooled serum 
σTEA-Low σTEA-High σTEA-Low σTEA-High 
ALB 6.0 10.6 5.3 9.3 
ALP 8.8 11.6 3.1 4.0 
ALT 1.5 3.6 3.6 8.6 
Ca 1.6 2.4 0.7 1.1 
Chol 79.9 NA 11.0 NA 
Crea 4.7 6.0 6.9 8.8 
GGT 3.4 NA NA NA 
Glu 9.5 NA 7.4 NA 
Phos –2.3 –1.3 –3.0 –1.8 
TBil 2.4 10.2 1.0 4.5 
TP 3.8 NA 2.4 NA 
Urea 2.6 3.7 5.2 7.3 
* TEA = total allowable error; ALB = albumin; ALP = alkaline phosphatase; ALT = alanine 332 
aminotransferase; Ca = calcium; Chol = cholesterol; Crea = creatinine; GGT = gamma-glutamyl 333 
transferase; Glu = glucose; Phos = phosphate; TBil = total bilirubin; TP = total protein; NA = not 334 
applicable (cannot be calculated). 335 
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Table 5. Measurement of analytes from canine clinical samples using the in-practice and 337 
reference analyzers.* 338 
Analyte r 
In-practice analyzer Reference analyzer 
P Median Range Median Range 
ALB (g/L) 0.91 33.5 15.9–44.9 26.8 12.8–25.8 <0.0001 
ALP (IU/L) 1.00 240 25–5400 115 8–2793 0.002 
ALT (IU/L) 0.97 54 8–364 53 6–447 0.800 
Ca (mmol/L) 0.78 2.47 1.01–3.34 2.65 1.17–3.78 0.009 
Chol (mmol/L) 0.98 5.54 1.79–15.39 5.35 1.76–17.58 0.522 
Crea (µmol/L) 0.93 87.4 45.4–321.0 71.0 33.0–308.0 0.008 
GGT (IU/L) 0.94 6 1–778 6 0–815 0.878 
Glu (mmol/L) 0.93 4.89 0.24–19.50 5.00 0.40–18.80 0.891 
Phos (mmol/L) 0.49 1.70 0.24–2.80 1.52 0.58–3.79 0.028 
TBil (µmol/L) 0.70 20.0 1.2–87.0 7.2 2.0–79.2 <0.0001 
TP (g/L) 0.93 64.3 28.5–83.6 59.3 27.2–80.2 0.002 
Urea (mmol/L) 0.97 6.7 2.2–35.6 5.9 2.0–34.5 0.277 
* P = significance of difference between the datasets for the 2 analyzers; ALB = albumin; ALP = 339 
alkaline phosphatase; ALT = alanine aminotransferase; Ca = calcium; Chol = cholesterol; Crea = 340 
creatinine; GGT = gamma-glutamyl transferase; Glu = glucose; Phos = phosphate; TBil = total 341 
bilirubin; TP = total protein. 342 
343 
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Table 6. Measurement of analytes from feline clinical samples using the in-practice and 344 
reference analyzers.* 345 
Analyte r 
In-practice analyzer Reference analyzer 
P Median Range Median Range 
ALB (g/L) 0.71 33.7 22.3–47.3 27.4 16.8–33.6 <0.0001 
ALP (IU/L) 0.93 72 3–1133 28 5–385 <0.0001 
ALT (IU/L) 0.88 35 2–820 61 23–960 0.0008 
Ca (mmol/L) 0.62 2.46 1.60–3.37 2.50 1.92–3.22 0.175 
Chol (mmol/L) 0.77 4.17 2.31–9.20 4.00 1.52–8.76 0.673 
Crea (µmol/L) 0.98 119.9 36.5–564.3 106.0 27.0–559.0 0.134 
GGT (IU/L) 0.25 2 1–12 1 1–5 0.002 
Glu (mmol/L) 0.86 5.35 2.59–11.63 5.40 2.60–13.20 0.880 
Phos (mmol/L) 0.81 1.30 0.90–2.60 1.58 0.99–3.19 <0.0001 
TBil (µmol/L) 0.86 10.1 3.5–367.0 4.4 1.9–207.0 <0.0001 
TP (g/L) 0.82 71.2 47.1–91.8 67.0 42.7–87.5 0.018 
Urea (mmol/L) 0.95 12.2 3.90–34 57 11.20 3.90–36.70 0.087 
* P = significance of difference between the data sets for the 2 analyzers; ALB = albumin; ALP 346 
= alkaline phosphatase; ALT = alanine aminotransferase; Ca = calcium; Chol = cholesterol; Crea 347 
= creatinine; GGT = gamma-glutamyl transferase; Glu = glucose; Phos = phosphate; TBil = total 348 
bilirubin; TP = total protein. 349 
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Table 7. Proportional error (slope), constant error (y-intercept), and bias for canine samples 351 
measured using the in-practice analyzer and relative to the reference analyzer.* 352 
Analyte 
Deming regression Bland–Altman 
Slope 95% CI y-intercept 95% CI Bias 95% LOA % in LOA 
ALB (g/L) 1.23 1.11–1.36 0.43 –2.92 to 3.79 6.5 2.2 to 10.8 91 
ALP (IU/L) 1.94 1.90–1.98 17.48 –4.53 to 39.49 278 –531 to 1087 95 
ALT (IU/L) 0.83 0.78–0.87 8.87 2.78 to 14.95 –8 –58 to 43 91 
Ca (mmol/L) 1.09 0.90–1.27 –0.40 –0.88 to 0.08 –0.18 –0.64 to 0.28 98 
Chol (mmol/L) 1.01 0.96–1.06 0.22 –0.11 to 0.56 0.28 –0.83 to 1.39 95 
Crea (µmol/L) 1.07 1.01–1.14 8.86 2.34 to 15.40 15.2 –9.4 to 39.8 92 
GGT (IU/L) 0.98 0.96–0.99 1.20 –0.34 to 2.74 0.5 –12.4 to 13.4 97 
Glu (mmol/L) 1.05 1.00–1.11 –0.20 –0.50 to 0.09 0.06 –0.94 to 1.06 100 
Phos (mmol/L) 0.61 0.41–0.81 0.75 0.41 to 1.10 0.11 –0.82 to 1.05 97 
TBil (µmol/L) 1.80 1.40–2.19 8.01 2.21 to 13.81 15.7 –7.1 to 38.5 95 
TP (g/L) 1.19 1.11–1.28 –5.46 –10.58 to 0.33 5.6 –1.7 to 12.8 95 
Urea (mmol/L) 1.07 1.03–1.11 0.21 –0.17 to 0.58 0.71 –1.19 to 2.62 98 
* CI = confidence interval; LOA = limits of agreement; ALB = albumin; ALP = alkaline 353 
phosphatase; ALT = alanine aminotransferase; Ca = calcium; Chol = cholesterol; Crea = 354 
creatinine; GGT = gamma-glutamyl transferase; Glu = glucose; Phos = phosphate; TBil = total 355 
bilirubin; TP = total protein. 356 
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Table 8. Proportional error (slope), constant error (y-intercept), and bias for feline samples 358 
measured using the in-practice analyzer and relative to the reference analyzer. 359 
Analyte 
Deming regression Bland–Altman 
Slope 95% CI y-intercept 95% CI Bias 95% LOA % in LOA 
ALB (g/L) 1.51 1.11–1.90 –7.28 –17.90 to 3.35 6.3 –0.2 to 12.9 90 
ALP (IU/L) 2.63 2.50–2.76 –3.95 –15.94 to 8.05 86 –151 to 323 97 
ALT (IU/L) 0.66 0.59–0.74 –4.27 –23.56 to 15.03 –54 –247 to 139 97 
Ca (mmol/L) 1.62 1.07–2.17 –1.63 –3.02 to –0.24 –0.08 –0.65 to 0.49 97 
Chol (mmol/L) 1.14 0.93–1.34 –0.41 –1.30 to 0.47 0.15 –1.38 to 1.67 95 
Crea (µmol/L) 1.02 0.99–1.06 12.37 6.64 to 18.10 15.5 –9.1 to 40.0 93 
GGT (IU/L) 5.24 1.16–9.32 –5.94 –13.96 to 2.08 1.1 –3.1 to 5.3 98 
Glu (mmol/L) 1.01 0.89–1.13 0.00 –0.73 to 0.74 0.08 –1.40 to 1.55 97 
Phos (mmol/L) 0.80 0.70–0.91 0.07 –0.11 to 0.24 –0.26 –0.66 to 0.15 93 
TBil (µmol/L) 1.62 1.53–1.72 2.07 –1.31 to 5.46 11.0 –31.3 to 53.2 98 
TP (g/L) 1.02 0.83–1.21 2.70 –10.08 to 15.49 4.0 –6.6 to 14.5 97 
Urea (mmol/L) 1.07 0.99–1.15 0.67 –0.40 to 1.75 1.48 –2.15 to 5.11 98 
* CI = confidence interval; LOA = limits of agreement; ALB = albumin; ALP = alkaline 360 
phosphatase; ALT = alanine aminotransferase; Ca = calcium; Chol = cholesterol; Crea = 361 
creatinine; GGT = gamma-glutamyl transferase; Glu = glucose; Phos = phosphate; TBil = total 362 
bilirubin; TP = total protein. 363 
